| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina and 2 Syndax Pharmaceuticals, Waltham, Massachusetts
Requests for reprints: Tso-Pang Yao, Department of Pharmacology and Cancer Biology, Box 3813, Duke University Medical Center, Durham, NC 27710. Phone: 919-613-8654; Fax. 919-668-3954; E-mail: yao00001{at}mc.duke.edu.
Key Words: HDAC6 deacetylation anoikis transformation HDACI
Histone deacetylase inhibitors (HDACI) are promising antitumor agents. Although transcriptional deregulation is thought to be the main mechanism underlying their therapeutic effects, the exact mechanism and targets by which HDACIs achieve their antitumor effects remain poorly understood. It is not known whether any of the HDAC members support robust tumor growth. In this report, we show that HDAC6, a cytoplasmic-localized and cytoskeleton-associated deacetylase, is required for efficient oncogenic transformation and tumor formation. We found that HDAC6 expression is induced upon oncogenic Ras transformation. Fibroblasts deficient in HDAC6 are more resistant to both oncogenic Ras and ErbB2-dependent transformation, indicating a critical role for HDAC6 in oncogene-induced transformation. Supporting this hypothesis, inactivation of HDAC6 in several cancer cell lines reduces anchorage-independent growth and the ability to form tumors in mice. The loss of anchorage-independent growth is associated with increased anoikis and defects in AKT and extracellular signal-regulated kinase activation upon loss of adhesion. Lastly, HDAC6-null mice are more resistant to chemical carcinogen-induced skin tumors. Our results provide the first experimental evidence that a specific HDAC member is required for efficient oncogenic transformation and indicate that HDAC6 is an important component underlying the antitumor effects of HDACIs. [Cancer Res 2008;68(18):7561–9]
This article has been cited by other articles:
![]() |
G. Floris, M. Debiec-Rychter, R. Sciot, C. Stefan, S. Fieuws, K. Machiels, P. Atadja, A. Wozniak, G. Faa, and P. Schoffski High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model Clin. Cancer Res., June 15, 2009; 15(12): 4066 - 4076. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Schrump Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3947 - 3957. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Haberland, A. Johnson, M. H. Mokalled, R. L. Montgomery, and E. N. Olson Genetic dissection of histone deacetylase requirement in tumor cells PNAS, May 12, 2009; 106(19): 7751 - 7755. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, C. C. Vos, A. Gjyrezi, M. Yoshida, F. R. Khuri, F. Tamanoi, and P. Giannakakou The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner J. Biol. Chem., April 10, 2009; 284(15): 9648 - 9655. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Azuma, T. Urano, K. Horie-Inoue, S.-i. Hayashi, R. Sakai, Y. Ouchi, and S. Inoue Association of Estrogen Receptor {alpha} and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells Cancer Res., April 1, 2009; 69(7): 2935 - 2940. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. D. Kekatpure, A. J. Dannenberg, and K. Subbaramaiah HDAC6 Modulates Hsp90 Chaperone Activity and Regulates Activation of Aryl Hydrocarbon Receptor Signaling J. Biol. Chem., March 20, 2009; 284(12): 7436 - 7445. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |